Incyte Corporation
HealthcareNASDAQ:INCY · NASDAQ Global Select
+$1.25 today
Vol 1.47M · Avg 1.54M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$5.4B of revenue converted into $1.4B of net income for the selected period. Gross margin is 92.5% and net margin is 27.0%, showing how much revenue survives after costs and taxes. EPS is $7.08, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1B +21.2% | $4.2B +14.8% | $3.7B +8.9% | $3.4B +13.7% | $3.0B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $372.1M +19.2% | $312.1M +22.4% | $255.0M +23.2% | $207.0M +37.1% | $151.0M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $4.8B +21.4% | $3.9B +14.2% | $3.4B +7.9% | $3.2B +12.4% | $2.8B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 92.8% +0.1pp | 92.6% -0.5pp | 93.1% -0.8pp | 93.9% -1.0pp | 94.9% | 9.8% | 28.9% | 38.3% |
| Research & Development | $2.1B -21.4% | $2.6B +60.2% | $1.6B +2.6% | $1.6B +8.8% | $1.5B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $1.4B +12.6% | $1.2B +5.7% | $1.2B +15.3% | $1.0B +35.5% | $739.6M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $3.4B -10.5% | $3.8B +37.4% | $2.8B +7.3% | $2.6B +15.4% | $2.2B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $93.3M +4.5% | $89.2M +8.0% | $82.7M +21.8% | $67.9M +17.3% | $57.8M | $374.2M | $1.2B | $631.8M |
| EBITDA | $1.8B +331.2% | $408.2M -55.6% | $919.4M +53.3% | $599.6M -4.8% | $630.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 34.2% +24.6pp | 9.6% -15.3pp | 24.9% +7.2pp | 17.7% -3.4pp | 21.1% | 5.6% | 46.3% | 42.0% |
| Operating Income | $1.3B +1225.6% | $101.3M -84.5% | $655.4M +10.8% | $591.6M +1.0% | $585.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 26.1% +23.7pp | 2.4% -15.3pp | 17.7% +0.3pp | 17.4% -2.2pp | 19.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $105.6M -18.0% | $128.7M | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $2.4M +6.5% | $2.3M -10.6% | $2.6M -4.3% | $2.7M +39.7% | $1.9M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $321.7M +49.4% | $215.3M +20.4% | $178.9M +386.1% | -$62.5M -307.7% | -$15.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $1.7B +425.7% | $316.6M -62.0% | $834.2M +57.7% | $529.1M -7.2% | $570.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 32.4% +24.9pp | 7.5% -15.1pp | 22.6% +7.0pp | 15.6% -3.5pp | 19.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $377.8M +33.0% | $284.0M +20.0% | $236.6M +25.6% | $188.5M +149.8% | -$378.1M | $1.3B | -$1.6B | $745.2M |
| Net Income | $1.3B +3845.0% | $32.6M -94.5% | $597.6M +75.4% | $340.7M -64.1% | $948.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | 25.0% +24.3pp | 0.8% -15.4pp | 16.2% +6.1pp | 10.0% -21.7pp | 31.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $7 +4018.8% | $0 -94.0% | $3 +74.5% | $2 -64.4% | $4 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $6 +4173.3% | $0 -94.3% | $3 +74.3% | $2 -64.4% | $4 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $195.2M -5.7% | $207.1M -7.4% | $223.6M +0.7% | $222.0M +0.7% | $220.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $200.7M -4.7% | $210.5M -6.8% | $225.9M +0.9% | $224.0M +0.8% | $222.1M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Biogen Inc.
NASDAQ:BIIB
$29.58B
Illumina, Inc.
NASDAQ:ILMN
$24.47B
Royalty Pharma plc
NASDAQ:RPRX
$23.72B
West Pharmaceutical Services, Inc.
NYSE:WST
$23.28B
Waters Corporation
NYSE:WAT
$23.15B
United Therapeutics Corporation
NASDAQ:UTHR
$23.02B
Quest Diagnostics Incorporated
NYSE:DGX
$22.46B
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
$17.13B
Genmab A/S
NASDAQ:GMAB
$15.37B
Tenet Healthcare Corporation
NYSE:THC
$15.25B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does INCY generate?
Incyte Corporation (INCY) reported $5.14B of revenue in fiscal 2025.
Is INCY profitable?
Incyte Corporation (INCY) reported $1.29B of net income, with a net margin of 25.0%.
Explore More
Continue the stock analysis
Jump to another research area for this company.